Schering-Plough Corporation 1995 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1995, for Schering-Plough Corporation, a holding company incorporated in New Jersey. The Company operates globally in the discovery, development, manufacturing, and marketing of pharmaceutical and health care products. Key segments include prescription drugs, animal health, over-the-counter (OTC) medicines, foot care, and sun care products. The Company employed approximately 20,100 people worldwide as of year-end, with significant operations in the United States and Puerto Rico.
Key Financial Metrics
Consolidated sales for continuing operations totaled $5,104 million in 1995, an increase from $4,537 million in 1994. Research and development expenditures were $656.9 million, representing approximately 13% of consolidated sales. Capital expenditures for environmental control purposes were approximately $16.6 million.
Sales by Major Product Groups (1995 vs. 1994 in millions):
| Product Group | 1995 Sales | 1994 Sales |
|---|---|---|
| Respiratory | $1,834 | $1,465 |
| Anti-infective and Anticancer | $1,031 | $939 |
| Dermatologicals | $515 | $488 |
| Cardiovasculars | $408 | $333 |
| Other Pharmaceuticals | $493 | $489 |
| OTC | $250 | $264 |
| Foot Care | $240 | $248 |
| Animal Health | $190 | $167 |
| Sun Care | $127 | $129 |
| Other Health Care Products | $16 | $15 |
| Total Consolidated Sales | $5,104 | $4,537 |
Note: Specific figures for net profit, operating margins, cash flow, and total debt are not provided in the text of this filing, as the detailed financial statements are incorporated by reference from the 1995 Annual Report to Shareholders.
Material Changes and Operational Highlights
- Discontinued Operations: The Company sold its contact lens business in 1995, reporting it as a discontinued operation.
- Generic Competition: In December 1995, the FDA granted marketing clearance to a generic albuterol metered-dose inhaler (MDI). This is expected to negatively affect future sales and profitability of the Company's PROVENTIL inhaler franchise. The Company responded by introducing its own generic albuterol inhaler through its Warrick subsidiary.
- Patent Expirations: The U.S. patent for PROVENTIL expired in December 1989, and its formulations have been subject to generic competition.
- Legal Settlements: The Company agreed to settle a federal antitrust class action for $22.1 million, payable over three years, subject to court approval.
Outlook, Risks, and Contingencies
Legal Proceedings:
- Estrogen Litigation: The Company is a defendant in over 95 lawsuits regarding synthetic estrogens, with total claims exceeding $2 billion. Management believes it is remote that material liability in excess of accrued amounts will be incurred.
- THEO-DUR Judgment: A $63.6 million judgment (including $57.5 million in punitive damages) was entered against the Company in 1994. The Company is appealing and has insurance coverage for amounts exceeding a $3 million retention.
- Antitrust Actions: The Company faces over 150 antitrust actions alleging price discrimination and conspiracy. Management believes these actions are without merit.
- Environmental: The Company is involved in Superfund proceedings as a potentially responsible party. Management deems it remote that material liability will exceed accrued amounts.
Regulatory and Market Risks:
- Government Regulation: The Company faces increasing pressure from managed care groups and government-mandated cost containment programs globally, including price cuts and restrictions on physician prescriptions.
- Foreign Operations: Risks include nationalization, expropriation, and foreign currency exchange rate fluctuations.
- Tax Incentives: Tax exemptions for Puerto Rico operations are being phased down under the Omnibus Budget Reconciliation Act of 1993.
Investor Verification Checklist
- Financial Statements: Verify net income, operating margins, and cash flow figures in the incorporated 1995 Annual Report to Shareholders, as they are not detailed in this text.
- PROVENTIL Impact: Assess the specific financial impact of the generic albuterol MDI approval on the respiratory segment's future revenue projections.
- Legal Reserves: Review the adequacy of accrued liabilities for the estrogen litigation and THEO-DUR appeal in the Notes to Consolidated Financial Statements.
- Antitrust Settlement: Confirm the status of the $22.1 million antitrust settlement approval by the court.
- Discontinued Operations: Review the financial results and tax implications of the sold contact lens business.